Efficacy, Safety, and Biomarkers of Neoadjuvant Bevacizumab, Radiation Therapy, and Fluorouracil in Rectal Cancer: A Multidisciplinary Phase II Study

• Published in: Journal of clinical oncology Vol. 27; no. 18; pp. 3020 - 3026
• Main Authors: Willett, Christopher G., Duda, Dan G., di Tomaso, Emmanuelle, Boucher, Yves, Ancukiewicz, Marek, Sahani, Dushyant V., Lahdenranta, Johanna, Chung, Daniel C., Fischman, Alan J., Lauwers, Gregory Y., Shellito, Paul, Czito, Brian G., Wong, Terence Z., Paulson, Erik, Poleski, Martin, Vujaskovic, Zeljko, Bentley, Rex, Chen, Helen X., Clark, Jeffrey W., Jain, Rakesh K.
• Format: Journal Article
• Language: English
• Published: Alexandria, VA American Society of Clinical Oncology 20.06.2009
• Subjects: Adult; Aged; Angiogenesis Inhibitors - therapeutic use; Antibodies, Monoclonal - therapeutic use; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic - administration & dosage; Bevacizumab; Biological and medical sciences; Biomarkers - blood; Cmod; Combined Modality Therapy; Endothelial Cells - cytology; Female; Fluorouracil - administration & dosage; Gastroenterology. Liver. Pancreas. Abdomen; Humans; Interleukin-6 - blood; Male; Medical sciences; Middle Aged; Neoadjuvant Therapy; Original Reports; Radn; Rectal Neoplasms - mortality; Rectal Neoplasms - radiotherapy; Rectal Neoplasms - surgery; Rectal Neoplasms - therapy; Stomach. Duodenum. Small intestine. Colon. Rectum. Anus; Tumors; Vascular Endothelial Growth Factor A; Antineoplastic agent; Rectal disease; Biological marker; Monoclonal antibody; Neoadjuvant treatment; Bevacizumab; Cancerology; Phase II trial; Intestinal disease; Antiangiogenic agent; Anorectal disease; Multidisciplinary; Fluorouracil; Enzyme; Fluoropyrimidine derivatives; Transferases; Treatment efficiency; Enzyme inhibitor; Malignant tumor; Rectum cancer; Thymidylate synthase; Radiotherapy; Vascular endothelium growth factor; Antimetabolic; Methyltransferases; Pyrimidine derivatives; Digestive diseases; Cancer

To assess the safety and efficacy of neoadjuvant bevacizumab with standard chemoradiotherapy in locally advanced rectal cancer and explore biomarkers for response. In a phase I/II study, 32 patients received four cycles of therapy consisting of: bevacizumab infusion (5 or 10 mg/kg) on day 1 of each...